Presence & RecognitionEvent: September 8, 2026
Immunic Therapeutics is hosting its Relapsing MS R&D Day tomorrow featuring discussions on RMS biology, persistent unmet needs, and the scientific rationale behind vidofludimus calcium, along with phase 3 ENSURE top-line data readout expected by the end of 2026.
Published
Signal category
Presence & Recognition
Quote
“What can attendees expect from Immunic's Relapsing MS R&D Day tomorrow?”
— Immunic Therapeutics team
Company
Immunic Therapeutics
Immunic (Nasdaq: IMUX) is a late-stage biotechnology company developing novel oral therapies for neurologic diseases.
- Industry
- Biotechnology Research
- Location
- New York City, US
- Company size
- 99 employees
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. Privacy Policy: https://imux.com/privacy-policy/
Founded 2016